Prophylactic rituximab prevents EBV PTLD in haplo-cord transplant recipients at high risk

Koen Van Besien, Lizamarie Bachier-Rodriguez, Michael Satlin, Maxwell A. Brown, Usama Gergis, Danielle Guarneri, Jingmei Hsu, Adrienne A. Phillips, Sebastian A. Mayer, Amrita D. Singh, Rosemary Soave, Adriana Rossi, Catherine B. Small, Thomas J. Walsh, Hanna Rennert, Tsiporah B. Shore

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Epstein–Barr virus (EBV) reactivation and post-transplant lymphoproliferative disorders (PTLD) are common and potentially fatal complications after allogeneic transplantation with mismatched donors and T-cell depletion. Haplo-cord transplantation combines a mismatched UCB graft with third-party cells. Conditioning involves thymoglobulin. EBV reactivation and PTLD were common in initial patients. As of March 2017, we administered a prophylactic dose of rituximab 375 mg/m2 pre-transplant. Among 147 patients who did not receive rituximab, the cumulative incidence of post-transplant EBV reactivation and of EBV PTLD was 13% and 8%, respectively. Among 51 who received pre-transplant rituximab, the incidences were 2% (p =.0017) and 0% (p =.04), respectively. There was no difference in time to hematopoietic recovery, in the incidence of CMV reactivation, of invasive blood stream infections or of proven or probable invasive fungal infections. Pre-transplant administration of rituximab is an effective and nontoxic intervention that drastically reduces EBV reactivation and PTLD in high-risk patients.

Original languageEnglish (US)
Pages (from-to)1693-1696
Number of pages4
JournalLeukemia and Lymphoma
Volume60
Issue number7
DOIs
StatePublished - Jun 7 2019
Externally publishedYes

Fingerprint

Lymphoproliferative Disorders
Viruses
Transplants
Incidence
Rituximab
Transplant Recipients
Homologous Transplantation
Transplantation
Tissue Donors
T-Lymphocytes

Keywords

  • EBV
  • Epstein–Barr virus
  • PTLD
  • rituximab
  • transplant toxicity

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Prophylactic rituximab prevents EBV PTLD in haplo-cord transplant recipients at high risk. / Van Besien, Koen; Bachier-Rodriguez, Lizamarie; Satlin, Michael; Brown, Maxwell A.; Gergis, Usama; Guarneri, Danielle; Hsu, Jingmei; Phillips, Adrienne A.; Mayer, Sebastian A.; Singh, Amrita D.; Soave, Rosemary; Rossi, Adriana; Small, Catherine B.; Walsh, Thomas J.; Rennert, Hanna; Shore, Tsiporah B.

In: Leukemia and Lymphoma, Vol. 60, No. 7, 07.06.2019, p. 1693-1696.

Research output: Contribution to journalArticle

Van Besien, K, Bachier-Rodriguez, L, Satlin, M, Brown, MA, Gergis, U, Guarneri, D, Hsu, J, Phillips, AA, Mayer, SA, Singh, AD, Soave, R, Rossi, A, Small, CB, Walsh, TJ, Rennert, H & Shore, TB 2019, 'Prophylactic rituximab prevents EBV PTLD in haplo-cord transplant recipients at high risk', Leukemia and Lymphoma, vol. 60, no. 7, pp. 1693-1696. https://doi.org/10.1080/10428194.2018.1543877
Van Besien, Koen ; Bachier-Rodriguez, Lizamarie ; Satlin, Michael ; Brown, Maxwell A. ; Gergis, Usama ; Guarneri, Danielle ; Hsu, Jingmei ; Phillips, Adrienne A. ; Mayer, Sebastian A. ; Singh, Amrita D. ; Soave, Rosemary ; Rossi, Adriana ; Small, Catherine B. ; Walsh, Thomas J. ; Rennert, Hanna ; Shore, Tsiporah B. / Prophylactic rituximab prevents EBV PTLD in haplo-cord transplant recipients at high risk. In: Leukemia and Lymphoma. 2019 ; Vol. 60, No. 7. pp. 1693-1696.
@article{65fac8e05bf9420c9f9b2c6d3b90a52a,
title = "Prophylactic rituximab prevents EBV PTLD in haplo-cord transplant recipients at high risk",
abstract = "Epstein–Barr virus (EBV) reactivation and post-transplant lymphoproliferative disorders (PTLD) are common and potentially fatal complications after allogeneic transplantation with mismatched donors and T-cell depletion. Haplo-cord transplantation combines a mismatched UCB graft with third-party cells. Conditioning involves thymoglobulin. EBV reactivation and PTLD were common in initial patients. As of March 2017, we administered a prophylactic dose of rituximab 375 mg/m2 pre-transplant. Among 147 patients who did not receive rituximab, the cumulative incidence of post-transplant EBV reactivation and of EBV PTLD was 13{\%} and 8{\%}, respectively. Among 51 who received pre-transplant rituximab, the incidences were 2{\%} (p =.0017) and 0{\%} (p =.04), respectively. There was no difference in time to hematopoietic recovery, in the incidence of CMV reactivation, of invasive blood stream infections or of proven or probable invasive fungal infections. Pre-transplant administration of rituximab is an effective and nontoxic intervention that drastically reduces EBV reactivation and PTLD in high-risk patients.",
keywords = "EBV, Epstein–Barr virus, PTLD, rituximab, transplant toxicity",
author = "{Van Besien}, Koen and Lizamarie Bachier-Rodriguez and Michael Satlin and Brown, {Maxwell A.} and Usama Gergis and Danielle Guarneri and Jingmei Hsu and Phillips, {Adrienne A.} and Mayer, {Sebastian A.} and Singh, {Amrita D.} and Rosemary Soave and Adriana Rossi and Small, {Catherine B.} and Walsh, {Thomas J.} and Hanna Rennert and Shore, {Tsiporah B.}",
year = "2019",
month = "6",
day = "7",
doi = "10.1080/10428194.2018.1543877",
language = "English (US)",
volume = "60",
pages = "1693--1696",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - Prophylactic rituximab prevents EBV PTLD in haplo-cord transplant recipients at high risk

AU - Van Besien, Koen

AU - Bachier-Rodriguez, Lizamarie

AU - Satlin, Michael

AU - Brown, Maxwell A.

AU - Gergis, Usama

AU - Guarneri, Danielle

AU - Hsu, Jingmei

AU - Phillips, Adrienne A.

AU - Mayer, Sebastian A.

AU - Singh, Amrita D.

AU - Soave, Rosemary

AU - Rossi, Adriana

AU - Small, Catherine B.

AU - Walsh, Thomas J.

AU - Rennert, Hanna

AU - Shore, Tsiporah B.

PY - 2019/6/7

Y1 - 2019/6/7

N2 - Epstein–Barr virus (EBV) reactivation and post-transplant lymphoproliferative disorders (PTLD) are common and potentially fatal complications after allogeneic transplantation with mismatched donors and T-cell depletion. Haplo-cord transplantation combines a mismatched UCB graft with third-party cells. Conditioning involves thymoglobulin. EBV reactivation and PTLD were common in initial patients. As of March 2017, we administered a prophylactic dose of rituximab 375 mg/m2 pre-transplant. Among 147 patients who did not receive rituximab, the cumulative incidence of post-transplant EBV reactivation and of EBV PTLD was 13% and 8%, respectively. Among 51 who received pre-transplant rituximab, the incidences were 2% (p =.0017) and 0% (p =.04), respectively. There was no difference in time to hematopoietic recovery, in the incidence of CMV reactivation, of invasive blood stream infections or of proven or probable invasive fungal infections. Pre-transplant administration of rituximab is an effective and nontoxic intervention that drastically reduces EBV reactivation and PTLD in high-risk patients.

AB - Epstein–Barr virus (EBV) reactivation and post-transplant lymphoproliferative disorders (PTLD) are common and potentially fatal complications after allogeneic transplantation with mismatched donors and T-cell depletion. Haplo-cord transplantation combines a mismatched UCB graft with third-party cells. Conditioning involves thymoglobulin. EBV reactivation and PTLD were common in initial patients. As of March 2017, we administered a prophylactic dose of rituximab 375 mg/m2 pre-transplant. Among 147 patients who did not receive rituximab, the cumulative incidence of post-transplant EBV reactivation and of EBV PTLD was 13% and 8%, respectively. Among 51 who received pre-transplant rituximab, the incidences were 2% (p =.0017) and 0% (p =.04), respectively. There was no difference in time to hematopoietic recovery, in the incidence of CMV reactivation, of invasive blood stream infections or of proven or probable invasive fungal infections. Pre-transplant administration of rituximab is an effective and nontoxic intervention that drastically reduces EBV reactivation and PTLD in high-risk patients.

KW - EBV

KW - Epstein–Barr virus

KW - PTLD

KW - rituximab

KW - transplant toxicity

UR - http://www.scopus.com/inward/record.url?scp=85061438555&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061438555&partnerID=8YFLogxK

U2 - 10.1080/10428194.2018.1543877

DO - 10.1080/10428194.2018.1543877

M3 - Article

C2 - 30741059

AN - SCOPUS:85061438555

VL - 60

SP - 1693

EP - 1696

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 7

ER -